Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

a phone keypad. If you'd like to withdraw your question, press star one again. Thank you. I'd now like to turn the conference over to Jody Sievers, Head of Investor Relations for Coherence Oncology. You may begin. Thank you, Jordan. Good afternoon and welcome to Coherence Oncology second quarter, 2025 earnings conference call. Joining me today to discuss our results are Denny Lanphier, Chief Executive Officer of Coherence, Brian McMichael, Chief Financial Officer, Dr. Rosh Diaz, Chief Medical Officer, Dr. Teresa Lavallee, Chief Scientific Officer, Chief Scientific and Development Officer, Mayor Goria Gauker, Executive Vice President, Commercial. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherence's current expectations about future events. Actual results may vary significantly and we undertake no duty to update or revise any forward-looking statement. Please see the press release that we issued today and our quarterly report on form 10Q for more information on risks and uncertainties. And now I'll turn the call over to Denny. Oh, thank you, Jody, and welcome all. In Q2, 2025, we completed our strategic repositioning and renamed our company Coherence Oncology to better reflect our mission. Today, in addition to reviewing the progress we made in growing our commercial revenue and advancing our clinical oncology programs ahead of key data readouts in the first half of 26, I wanna take the opportunity to introduce you to our new company and highlight what sets us apart. Today, I'll be focusing for you on three main points of Coherence Oncology. First, who we are as a company in terms of science, products, and mission. Second, what we are doing clinically and strategically to advance that mission thro...